A7074258
Ammoniumpyrrolidinedithiocarbamate , 10mMinDMSO , 5108-96-3
Synonym(s):
PDC;APDC;PDTC;Pyrrolidine-1-dithiocarboxylic acid ammonium salt;1-Pyrrolidinecarbodithioic acid ammonium salt
CAS NO.：5108-96-3
Empirical Formula: C5H9NS2.H3N
Molecular Weight: 164.3
MDL number: MFCD00012720
EINECS: 225-834-4
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB159.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 153-155 °C(lit.) |
| Density | 1.117 (estimate) |
| refractive index | 1.5300 (estimate) |
| storage temp. | Store at +2°C to +8°C. |
| solubility | 190g/l |
| form | Powder/Solid |
| color | White to off-white |
| PH | 6-7 (50g/l, H2O, 20℃) |
| Water Solubility | 50 g/L (20 ºC) |
| Sensitive | Hygroscopic |
| BRN | 3730472 |
| Stability: | Stable. Incompatible with strong oxidizing agents. |
Description and Uses
Pyrrolidinedithiocarbamic acid (PDTC) is a metal chelating compound that potently and reversibly inhibits NF-κB activation in vitro (100 μM). At 300 μM, it prevents TNF-α gene expression and protein production in human monocytes after LPS application. In vascular smooth muscle cells, PDTC (10 μM) arrests the cell cycle at the G1 phase with upregulation of p21Cip1 through the p38 MAPK pathway. PDTC (100 μM) also has antioxidant properties.
Ammonium pyrrolidinedithiocarbamate has been used:
- to inhibit nuclear factor κB (NF-κB) mobilization and TNF (tumor necrosis factor) production in human monocytes
- to reduce neutrophil activity in rats
- to prevent Ca2+ influx in adriamycin (ADR)-treated podocytes
to abrogate the microRNA-146a promoter luciferase reporter activity in human brain cells
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P261-P280a-P304+P340-P305+P351+P338-P405-P501a |
| Hazard Codes | Xi,Xn |
| Risk Statements | 36/37/38-22 |
| Safety Statements | 26-36-37/39 |
| WGK Germany | 3 |
| F | 3 |
| TSCA | Yes |
| HS Code | 29339990 |
